InnovAge (INNV) Q4 2026 earnings review
Operational Turnaround Complete; Margins Expand Despite Looming Rate Pressures
InnovAge capped off its fiscal 2026 with a decisive Q4, generating $262 million in revenue (+18% YoY) and returning to a positive Net Income of $9.8 million. The core PACE operational model is showing tremendous leverage: Center-level Contribution Margin surged to 23.9% from 18.6% a year ago. While management had proactively warned in Q3 about a tougher FY27 rate environment, their official FY27 guidance still targets $105-$115 million in Adjusted EBITDA—a healthy 16% YoY increase at the midpoint. Top-line growth will decelerate into the single digits, but the profitability engine is now firmly established.
🐂 Bull Case
Center-level contribution margins expanded by over 500 basis points YoY in Q4 to 23.9%. In-sourcing pharmacy and optimizing clinical utilization have created a sustainable profitability floor.
After a sluggish Q3 that saw only 40 net participant additions, Q4 bounced back with 180 net additions, ending the year at 8,230. Momentum is carrying into FY27.
🐻 Bear Case
FY27 revenue guidance implies roughly 7.8% YoY growth, a sharp deceleration from FY26's 15.9%. This directly reflects the Medicare/Medicaid rate headwinds management warned about in Q3.
While Q4 was clean, Q3 saw a massive $51.9M litigation charge that wiped out quarterly net income. Unpredictable regulatory and legal costs remain a background risk in the PACE sector.
⚖️ Verdict: 🟢
Bullish. The fundamental turnaround of the center-level operating model is undeniably successful. Even with top-line rate pressures compressing revenue growth in FY27, InnovAge's ability to drive double-digit EBITDA growth demonstrates highly resilient operating leverage.
Key Themes
Center-Level Margins Defy Rate Gravity
A year ago, Center-level Contribution Margin was 18.6%. In 26Q4, it hit 23.9%. This 530 bps expansion proves that internal cost controls—specifically reducing nursing facility utilization and the in-sourcing of pharmacy—are structural wins that are vastly outweighing any temporary rate stagnation.
FY27 Rate Headwinds Realized in Guidance
In Q3, management proactively warned that FY27 would bring Medicare rate increases of only 1.5% to 2.0% and constrained state Medicaid budgets. The FY27 revenue guidance confirms this reality, implying top-line growth of ~7.8%, effectively cutting the FY26 growth rate (15.9%) in half.
Census Additions Bounce Back
Q3 saw sequential net enrollment stall at just +40 participants. Q4 demonstrated a re-acceleration, adding 180 net participants to finish the year at 8,230 (+6.3% YoY). FY27 guidance points to 8,625–8,850 participants, representing an achievable ~500 net additions for the year.
Lingering Shadow of Corporate Overhead Volatility
While Q4 Corporate G&A normalized to $33.1M (12.6% of revenue), investors cannot ignore the Q3 shock where G&A spiked to $76.5M due to a $51.9M litigation liability. The company operates in a highly scrutinized regulatory environment, and margin gains can be quickly erased by legal and compliance settlements.
PACE Model Proving Superior to Medicare Advantage
As traditional Medicare Advantage plans grapple with bruising utilization spikes and harsh V28 risk model transitions, InnovAge's 'closed-loop' PACE model is shining. Direct control over both care delivery and cost containment provides a defensive moat against the macro utilization trends hurting the broader VBC (Value-Based Care) sector.
Other KPIs
Represented 12.6% of revenue, down significantly from the distorted 30.4% in 26Q3 (which was impacted by litigation). However, it remains higher than the $27.8M (12.6% of revenue) in the prior year period, showing that overhead costs are growing in lockstep with revenue, neutralizing potential G&A leverage.
Increased 16% YoY from $72.0 million. This grew slightly slower than revenue (+18%), driving the core margin expansion. Cost controls here are directly linked to better discharge planning and managing external provider usage.
Guidance
Decelerating. The midpoint ($1,067.5M) implies a 7.8% YoY growth rate. This is roughly half of the 15.9% growth achieved in FY26, directly reflecting the tighter state and federal capitation rate environment anticipated by management.
Stable/Accelerating margin. The midpoint ($110M) implies 16.3% YoY growth. Achieving 16% bottom-line growth on 8% top-line growth means EBITDA margins are expected to climb above 10.3%, hitting the company's long-term double-digit target.
Stable. The midpoint of 8,737 implies roughly 500 net new additions during the year, or roughly 6.1% growth from the FY26 exit census. This aligns with the historical mid-single-digit organic pace.
Key Questions
Litigation Liability Closure
The $52 million litigation charge in Q3 severely impacted GAAP earnings. Is this matter fully settled, and what ongoing compliance monitoring costs are embedded in the FY27 Corporate G&A guidance?
Florida De Novo Trajectory
New centers like Orlando and Tampa were historical drags on profitability. Are these centers crossing the breakeven threshold in FY27, or will de novo losses remain in the $11M-$13M range?
Rate Environment Breakdown
Can you bifurcate the FY27 revenue guidance to show the explicit pricing assumptions for Medicare versus Medicaid, and detail how you plan to manage states that are facing severe budget shortfalls?